References
[1] Moschetti, K., Cummings, P. L., Sorvillo, F., and Kuo, T. (2012)
Burden of Alzheimer’s disease-related mortality in the United States,
1999-2008, Journal of the American Geriatrics Society 60,
1509-1514.
[2] James, B. D., Leurgans, S. E., Hebert, L. E., Scherr, P. A.,
Yaffe, K., and Bennett, D. A. (2014) Contribution of Alzheimer disease
to mortality in the United States, Neurology 82,
1045-1050.
[3] Goure, W. F., Krafft, G. A., Jerecic, J., and Hefti, F. (2014)
Targeting the proper amyloid-beta neuronal toxins: a path forward for
Alzheimer’s disease immunotherapeutics, Alzheimers Res Ther
6 , 42.
[4] De Strooper, B., Vassar, R., and Golde, T. (2010) The
secretases: enzymes with therapeutic potential in Alzheimer disease,
Nat Rev Neurol 6 , 99-107.
[5] Gardberg, A. S., Dice, L. T., Ou, S., Rich, R. L., Helmbrecht,
E., Ko, J., Wetzel, R., Myszka, D. G., Patterson, P. H., and Dealwis, C.
(2007) Molecular basis for passive immunotherapy of Alzheimer’s disease,
Proc Natl Acad Sci U S A 104 , 15659-15664.
[6] Cummings, J. L., Morstorf, T., and Zhong, K. (2014) Alzheimer’s
disease drug-development pipeline: few candidates, frequent failures,
Alzheimers Res Ther 6 , 37.
[7] De Strooper, B. (2010) Proteases and proteolysis in Alzheimer
disease: a multifactorial view on the disease process,
Physiological reviews 90 , 465-494.
[8] Rembach, A., Faux, N. G., Watt, A. D., Pertile, K. K., Rumble,
R. L., Trounson, B. O., Fowler, C. J., Roberts, B. R., Perez, K. A., Li,
Q. X., Laws, S. M., Taddei, K., Rainey-Smith, S., Robertson, J. S.,
Vandijck, M., Vanderstichele, H., Barnham, K. J., Ellis, K. A., Szoeke,
C., Macaulay, L., Rowe, C. C., Villemagne, V. L., Ames, D., Martins, R.
N., Bush, A. I., Masters, C. L., and group, A. r. (2014) Changes in
plasma amyloid beta in a longitudinal study of aging and Alzheimer’s
disease, Alzheimers Dement 10, 53-61.
[9] Walti, M. A., Ravotti, F., Arai, H., Glabe, C. G., Wall, J. S.,
Bockmann, A., Guntert, P., Meier, B. H., and Riek, R. (2016)
Atomic-resolution structure of a disease-relevant Abeta(1-42) amyloid
fibril, Proc Natl Acad Sci U S A 113, E4976-4984.
[10] Bitan, G., Kirkitadze, M. D., Lomakin, A., Vollers, S. S.,
Benedek, G. B., and Teplow, D. B. (2003) Amyloid β-protein (Aβ)
assembly: Aβ40 and Aβ42 oligomerize through distinct pathways,
Proc Natl Acad Sci U S A 100 , 330-335.
[11] Tomiyama, T., Nagata, T., Shimada, H., Teraoka, R., Fukushima,
A., Kanemitsu, H., Takuma, H., Kuwano, R., Imagawa, M., Ataka, S., Wada,
Y., Yoshioka, E., Nishizaki, T., Watanabe, Y., and Mori, H. (2008) A new
amyloid β variant favoring oligomerization in Alzheimer’s-type dementia,
Ann Neurol 63 , 3773-3787.
[12] Wakutani, Y., Watanabe, K., Adachi, Y., Wada-Isoe, K., Urakami,
K., Ninomiya, H., Saido, T. C., Hashimoto, T., Iwatsubo, T., and
Nakashima, K. (2004) Novel amyloid precursor protein gene missense
mutation (D678N) in probable familial Alzheimer’s disease, J
Neurol Neurosurg Psychiatry 75, 1039-1042.
[13] Kamino, K., Sato, S., Sakaki, Y., Yoshiiwa, A., Nishiwaki, Y.,
Takeda, M., Tanabe, H., Nishimura, T., Ii, K., Stgeorgehyslop, P. H.,
Miki, T., and Ogihara, T. (1996) Three Different Mutations Of Presenilin
1 Gene In Early-Onset Alzheimers Disease Families, Neuroscience
Letters 208, 195-198.
[14] Grabowski, T. J., Cho, H. S., Vonsattel, J. P. G., Rebeck, G.
W., and Greenberg, S. M. (2001) Novel amyloid precursor protein mutation
in an Iowa family with dementia and severe cerebral amyloid angiopathy,
Annals of Neurology 49 , 697-705.
[15] Nilsberth, C., Westlind-Danielsson, A., Eckman, C. B., Condron,
M. M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D. B.,
Younkin, S. G., Naslund, J., and Lannfelt, L. (2001) The ’Arctic’ APP
mutation (E693G) causes Alzheimer’s disease by enhanced Abeta
protofibril formation, Nat Neurosci 4, 887-893.
[16] Kamino, K., Orr, H. T., Payami, H., Wijsman, E. M., Alonso, E.,
Pulst, S. M., Anderson, L., O’dahl, S., Nemens, E., White, J. A.,
Sadovnick, A. D., Ball, M. J., Kayue, J., Warren, A., McInnis, M.,
Antonarakis, S. T., Korenberg, J. R., Sharma, V., Kukull, W., Larson,
E., Heston, L. L., Martin, G. M., Bird, T. D., and Schellenberg, G. D.
(1992) Linkage and mutational analysis of familial Alzheimer disease
kindreds for the APP gene region, American Journal of Human
Genetics 51, 998-1014.
[17] Tagliavini, F., Rossi, G., Padovani, A., Magoni, M., Andora,
G., Sgarzi, M., Bizzi, A., Savioardo, M., Carella, F., Morbin, M.,
Giaccone, G., and Bugiani, O. (1999) A new βPP mutation related to
hereditary cerebral hemorrhage, Alzheimer’s Reports 2
(Suppl.), S28.
[18] Van Broeckhoven, C., Haan, J., Bakker, E., Hardy, J. A., Van
Hul, W., Wehnert, A., Vegter-Van der Vlis, M., and Roos, R. A. (1990)
Amyloid β protein precursor gene and hereditary cerebral hemorrhage with
amyloidosis (Dutch), Science 248, 1120-1122.
[19] Levy, E., Carman, M. D., Fernandez-Madrid, I. J., Power, M. D.,
Lieberburg, I., van Duinen, S. G., Bots, G. T., Luyendijk, W., and
Frangione, B. (1990) Mutation of the Alzheimer’s disease amyloid gene in
hereditary cerebral hemorrhage, Dutch-type, Science 248,
1124-1126.
[20] Hendriks, L., van Duijn, C. M., Cras, P., Cruts, M., Van Hul,
W., van Harskamp, F., Warren, A., McInnis, M. G., Antonarakis, S. E.,
Martin, J. J., Hofman, A., and Van Broeckhoven, C. (1992) Presenile
dementia and cerebral haemorrhage linked to a mutation at codon 692 of
the b-amyloid precursor protein gene, Nature Genetics 1,
218-221.
[21] Janssen, J. C., Beck, J. A., Campbell, T. A., Dickinson, A.,
Fox, N. C., Harvey, R. J., Houlden, H., Rossor, M. N., and Collinge, J.
(2003) Early onset familial Alzheimer’s disease: Mutation frequency in
31 families, Neurology 60, 235-239.
[22] Di Fede, G., Catania, M., Morbin, M., Rossi, G., Suardi, S.,
Mazzoleni, G., Merlin, M., Giovagnoli, A. R., Prioni, S., Erbetta, A.,
Falcone, C., Gobbi, M., Colombo, L., Bastone, A., Beeg, M., Manzoni, C.,
Francescucci, B., Spagnoli, A., Cantù, L., Del Favero, E., Levy, E.,
Salmona, M., and Tagliavini, F. (2009) A recessive mutation in the APP
gene with dominant-negative effect on amyloidogenesis, Science
323 , 1473.
[23] Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson,
P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D.,
Maloney, J., Hoyte, K., Gustafson, A., Liu, Y., Lu, Y., Bhangale, T.,
Graham, R. R., Huttenlocher, J., Bjornsdottir, G., Andreassen, O. A.,
Jonsson, E. G., Palotie, A., Behrens, T. W., Magnusson, O. T., Kong, A.,
Thorsteinsdottir, U., Watts, R. J., and Stefansson, K. (2012) A mutation
in APP protects against Alzheimer’s disease and age-related cognitive
decline, Nature 488, 96-99.
[24] Rothemund, S., Beyermann, M., Krause, E., Krause, G., Bienert,
M., Hodges, R. S., Sykes, B. D., and Sonnichsen, F. D. (1995) Structure
effects of double D-amino acid replacements: a nuclear magnetic
resonance and circular dichroism study using amphipathic model helices,
Biochemistry 34 , 12954-12962.
[25] Krause, E., Beyermann, M., Dathe, M., Rothemund, S., and
Bienert, M. (1995) Location of an amphipathic alpha-helix in peptides
using reversed-phase HPLC retention behavior of D-amino acid analogs,
Analytical chemistry 67 , 252-258.
[26] Wieprecht, T., Dathe, M., Schumann, M., Krause, E., Beyermann,
M., and Bienert, M. (1996) Conformational and functional study of
magainin 2 in model membrane environments using the new approach of
systematic double-D-amino acid replacement, Biochemistry
35 , 10844-10853.
[27] Raskatov, J., and Teplow, D. (2017) Using chirality to probe
the structure and function of disordered proteins, submitted.
[28] Warner, C. J., Dutta, S., Foley, A. R., and Raskatov, J. A.
(2016) Introduction of d-Glutamate at a Critical Residue of Abeta42
Stabilizes a Prefibrillary Aggregate with Enhanced Toxicity,
Chemistry 22 , 11967-11970.
[29] Kaneko, I., Morimoto, K., and Kubo, T. (2001) Drastic neuronal
loss in vivo by beta-amyloid racemized at Ser(26) residue: conversion of
non-toxic [D-Ser(26)]beta-amyloid 1-40 to toxic and
proteinase-resistant fragments, Neuroscience 104,
1003-1011.
[30] Walsh, D. M., Lomakin, A., Benedek, G. B., Condron, M. M., and
Teplow, D. B. (1997) Amyloid β-protein fibrillogenesis: detection of a
protofibrillar intermediate, J Biol Chem 272, 22364-22372.
[31] Bitan, G., Lomakin, A., and Teplow, D. B. (2001) Amyloid
β-protein oligomerization: prenucleation interactions revealed by
photo-induced cross-linking of unmodified proteins, J Biol Chem
276 , 35176-35184.
[32] Urbanc, B., Cruz, L., Yun, S., Buldyrev, S. V., Bitan, G.,
Teplow, D. B., and Stanley, H. E. (2004) In silico study of amyloid
β-protein folding and oligomerization, Proc Natl Acad Sci U S A
101 , 17345-17350.
[33] LeVine, H. (1993) Thioflavine T interaction with synthetic
Alzheimer’s disease β-amyloid peptides: detection of amyloid aggregation
in solution, Protein Sci 2, 404-410.
[34] LeVine, H. (1999) Quantification of β-sheet amyloid fibril
structures with thioflavin T, Methods Enzymol 309,
274-284.
[35] Naiki, H., and Nakakuki, K. (1996) First-order kinetic model of
Alzheimer’s β-amyloid fibril extension in vitro, Lab Invest
74 , 374-383.
[36] Kirkitadze, M. D., Condron, M. M., and Teplow, D. B. (2001)
Identification and characterization of key kinetic intermediates in
amyloid β-protein fibrillogenesis, J Mol Biol 312,
1103-1119.
[37] Barrow, C. J., Yasuda, A., Kenny, P. T., and Zagorski, M. G.
(1992) Solution conformations and aggregational properties of synthetic
amyloid β-peptides of Alzheimer’s disease. Analysis of circular
dichroism spectra, J Mol Biol 225, 1075-1093.
[38] Teplow, D. B. (2006) Preparation of amyloid β-protein for
structural and functional studies, Methods Enzymol 413,
20-33.
[39] Ono, K., Condron, M. M., and Teplow, D. B. (2009)
Structure-neurotoxicity relationships of amyloid β-protein oligomers,
Proc Natl Acad Sci U S A 106 , 14745-14750.
[40] Baumketner, A., Bernstein, S. L., Wyttenbach, T., Lazo, N. D.,
Teplow, D. B., Bowers, M. T., and Shea, J. E. (2006) Structure of the
21-30 fragment of amyloid β-protein, Protein Sci 15,
1239-1247.
[41] Lazo, N. D., Grant, M. A., Condron, M. C., Rigby, A. C., and
Teplow, D. B. (2005) On the nucleation of amyloid β-protein monomer
folding, Protein Sci 14, 1581-1596.
[42] Roychaudhuri, R., Yang, M., Deshpande, A., Cole, G. M.,
Frautschy, S., Lomakin, A., Benedek, G. B., and Teplow, D. B. (2013)
C-terminal turn stability determines assembly differences between Aβ40
and Aβ42, J Mol Biol 425, 292-308.
[43] Gessel, M. M., Wu, C., Li, H., Bitan, G., Shea, J. E., and
Bowers, M. T. (2012) Aβ(39-42) modulates Aβ oligomerization but not
fibril formation, Biochemistry 51, 108-117.
[44] de Groot, N. S., Parella, T., Aviles, F. X., Vendrell, J., and
Ventura, S. (2007) Ile-phe dipeptide self-assembly: clues to amyloid
formation, Biophys J 92, 1732-1741.
[45] Colvin, M. T., Silvers, R., Frohm, B., Su, Y., Linse, S., and
Griffin, R. G. (2015) High resolution structural characterization of
Aβ42 amyloid fibrils by MAS NMR, J Am Chem Soc.